The Children's Regional Hospital at Cooper/Cooper Medical School of Rowan University, Camden, NJ, USA.
AESARA Inc., Chapel Hill, NC, USA.
J Perinatol. 2023 Aug;43(8):982-990. doi: 10.1038/s41372-023-01690-9. Epub 2023 May 15.
To provide the best clinical practice guidance for surfactant use in preterm neonates with respiratory distress syndrome (RDS). The RDS-Neonatal Expert Taskforce (RDS-NExT) initiative was intended to add to existing evidence and clinical guidelines, where evidence is lacking, with input from an expert panel.
An expert panel of healthcare providers specializing in neonatal intensive care was convened and administered a survey questionnaire, followed by 3 virtual workshops. A modified Delphi method was used to obtain consensus around topics in surfactant use in neonatal RDS.
Statements focused on establishing RDS diagnosis and indicators for surfactant administration, surfactant administration methods and techniques, and other considerations. After discussion and voting, consensus was achieved on 20 statements.
These consensus statements provide practical guidance for surfactant administration in preterm neonates with RDS, with a goal to contribute to improving the care of neonates and providing a stimulus for further investigation to bridge existing knowledge gaps.
为患有呼吸窘迫综合征(RDS)的早产儿使用表面活性剂提供最佳临床实践指导。RDS-新生儿专家工作组(RDS-NExT)计划旨在通过专家小组的意见,在缺乏证据的情况下,补充现有证据和临床指南。
召集了专门从事新生儿重症监护的医疗保健提供者专家组,并对他们进行了问卷调查,随后进行了 3 次虚拟研讨会。使用改良 Delphi 方法就新生儿 RDS 中表面活性剂使用的相关主题达成共识。
各项陈述侧重于建立 RDS 诊断和表面活性剂给药指标、表面活性剂给药方法和技术以及其他注意事项。经过讨论和投票,就 20 项声明达成了共识。
这些共识性声明为患有 RDS 的早产儿使用表面活性剂提供了实用指导,旨在改善对新生儿的护理,并为进一步研究提供动力,以弥合现有知识差距。